2nd European ATTR amyloidosis meeting

06 September, 2019

Large sem t%c3%adtulo

BSIM has attended the 2nd European ATTR amyloidosis Meeting for Doctors and Patients, witnessing the most recent advances in the ATTR therapeutics field and discussing the current challenges faced by patients all over the world. Our CEO seized the opportunity to update physicians and patient associations on the progress of our Neurotera program, geared to the development of transthyretin stabilizers that address both peripheral nervous system (PNS) and central nervous system (CNS)-associated manifestations of hereditary ATTR with polyneuropathy.

By continuing to browse the site, you expressly agree that cookies will be stored on your computer to help measure statistics of visits and improve the quality of the contents offered.Learn more